ITGAM (Integrin, alpha M)

In vivo neutralization of CCL20 resulted in reduced tumor volume, prolonged survival, and decreased M-MDSCs, thus affirming the role of CCL20 in mediating immunosuppression. Our findings underscore the KITENIN-CCL20 axis as a promising target for alleviating the immunosuppressive TME in GBM, potentially unlocking new avenues for GBM immunotherapy.

These findings indicate that histotripsy induces a systemic antitumor immune response that potentiates chemotherapy efficacy in this model of metastatic NB. Mechanical ablation with histotripsy drives systemic antitumor immunity, reshapes the tumor microenvironment, and enhances chemotherapy efficacy in a syngeneic model of metastatic, high-risk neuroblastoma.

Furthermore, following phagocytosis, CAR-monocytes induced antigen-specific CD8+ T cell activation via antigen presentation. Collectively, these findings highlight CD32a-based and combinatorial ICD designs as a framework for functionally tuned CAR-M platform for solid tumor immunotherapy and anti-viral applications.

The t(16;21)(p11;q22) FUS::ERG fusion gene is rare in pediatric AML and associated with poor prognosis. Allo-HSCT may mitigate the adverse prognostic impact of the FUS::ERG fusion gene and contribute to prolonged survival.

Flow cytometry confirmed successful experimental manipulation of TME populations, with reduced FAP + CAFs (45.54%→22.01%) and CD11b+ TAMs (35.03%→24.18%) following respective gene depletion. We characterized RNF157 expression patterns in HCC at single-cell resolution and established a prognostic signature with moderate predictive performance requiring independent validation before clinical application.

In addition to its direct cytotoxicity, liriopein C treatment enhanced macrophage-mediated tumor cell clearance in vivo, significantly increasing the uptake of cancer cells by F4/80+CD11b+ peritoneal macrophages. These findings demonstrate that liriopeins possess dual antitumor and immunomodulatory activity, highlighting their potential as natural product-inspired leads for cancer immunochemotherapy.

TCN augments the differentiation-inducing activity of ATRA and promotes partial myelomonocytic differentiation, even in ATRA-resistant AML cells. Combination of TCN with established differentiation therapy may provide a strategy to overcome differentiation blockade in AML.

Collectively, both SPIONs attenuate complement activation, indicating high biocompatibility. Based on the early immunological responses, DS-SPIONs display a pro-healing immune profile suitable for regenerative drug delivery, whereas HP-SPIONs induce pro-inflammatory responses that may be leveraged for anticancer immunotherapy.

In this study, we revealed for the first time that FMD/fasting coordinates NRF1-UPS and Trex1/Sting-mediated type I interferon responses in TAMs that contribute to suppressing tumour growth. Graphical abstract: FMD upregulates the entry of NRF1 into the TAM nucleus to promote gene expression of proteasome subunits, which induces the ubiquitin/proteasome-dependent proteolysis of Trex1, leading to derepression of the cGAS-Sting-IFNβ axis. On the other hand, FMD triggers increasing of mtDNA in TAMs, promoting the cGAS-Sting-IFNβ axis to release IFNβ. In myeloid NRF1 knockout TAMs, transcriptional levels of proteasome subunits are reduced, resulting in impaired proteolysis of Trex1 and its subsequent accumulation during fasting. Then, Trex1 binds to mtDNA, directing the inhibition of the cGAS-Sting-IFNβ axis and inhibiting IFNβ secretion of macrophages.

IP PTX promotes the recruitment and activation of eosinophils with potent antitumor activity in the peritoneal cavity. Early post-treatment abdominal eosinophilia is a robust prognostic biomarker and may represent a promising therapeutic target to enhance the efficacy of IP chemotherapy in patients with PM from GC.

CDK11 inhibition by OTS964 effectively suppresses RTK growth through cell cycle arrest and RNA splicing inhibition, leading to apoptosis. OTS964 shows potent anti-tumor activity and tolerability, supporting CDK11 as a promising therapeutic target for RTK and related SMARCB1-deficient cancers.

Our research indicates that apheresis-derived granulocytes and pooled GCs do not differ enough to not consider more frequent use of the latter in daily clinical practice. Moreover, we concluded that gamma irradiation does not worsen the quality of granulocyte components, and freshly collected GCs should be preferred.